In several studies, treatment with DPP-IV inhibitors and GLP-1 receptor agonists was shown to improve blood glucose control in type 2 diabetic patients without increasing the risk of hypoglycemia. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.